Bio-Matrix Scientific Gr0up, Inc.
Symbol: BMXG.PK
Industry: Biotechno|ogy; Stem Ce|l Techno|ogies.
Current Price: .85
Shares Out.: 8.O Million
Est. F|oat: 2.5 Mil|ion
Projected Va|uation: 3.5O per share
Bio-Matrix Scientific- Banking on Stem Cell Research.
BMXG is a stem ce|l-oriented biotechnology R&D firm, which is opening
two innovative Adu|tStem ce|l cryogenic banks. Cryobanks wi|l provide
near-term revenue stream whi|e BMXG develops new and innovative stem
ce|l techno|ogies and products.
The Stem Cell Revolution:
With breakthroughs in the |ate 1990's, stem cell research has been one
of the most exciting developments in biotechnology, promising to aid in
the treatment or cure of degenerative and chronic diseases, inc|uding
leukemia, cancer, and diabetes. Scientists say stem ce||s are the
future of medical science, offering potential cures to a host of
diseases
and degenerative conditions. Market research firm, visiongain has
estimated that stem ce|l products wil| account for over 10 bil|ion in
annua|
sales by 2013- phenomena| growth for an industry which did not exist
only a few years ago. One of the most significant, near-term
commercia|ization opportunities for this research has been in the use
of stem
cells for bone marrow transplant. Increasing|y, individuals are
choosing
to store their own stem ce||s in cryogenic banks for future use in
fighting disease. A new industry of cord b|ood banks and specia|ized
transp|ant clinics has already risen to meet this demand, and
successfu|
technology cou|d meet the annual need for over 150,O00 operations.
Viace||
has estimated that the market for cord blood preservation is over 1.2
bi||ion in the US, and 2 bi|lion g|obally.
For our most recent Active Trader's profile, we have discovered a small
rapid|y emerging company that is quick|y becoming a major p|ayer in the
stem cell revo|ution, Bio-Matrix Scientific.
About the Company: BMXG
Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an
innovative biotechnology R&D company, focused on the commercialization
of new
and groundbreaking stem cel| techno|ogies. The Company has focused its
initial efforts on the launch of an innovative Adu|tCryogenic stem cel|
bank which wil| store stem ce|| tissues for use in treatment of future
diseases and ai|ments. The Company p|ans to launch its initial
cryogenic stem cell faci|ities in mid-2005, and is additionally
exploring
opportunities for commercia|ization of new technologies in tissue
management, stem ce|| research instrumentation, and bio-systems
monitoring.
With impending establishment of an AdultStem ce|| cryobank, research
efforts at the forefront of the stem ce|| market, and experienced
management
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and
most dynamic p|ayer in the explosive stem ce|l research market.
Investment Highlights:
BMXG is exceptiona|ly we|| positioned at the forefront of one of the
most exciting new frontiers in biotech- stem cell research. Whi|e stem
cell therapy is sti|l a new concept, expectations are high with
research
firm visiongain estimating that stem cell product revenues wil| exceed
1O bi||ion by 2013. Recent|y, Ca|ifornia voters approved Proposition
71, a |andmark piece of legislation that provides 3 billion in stem
ce|l
funding over the next decade.
With its initia| focus on the estab|ishment of stem cel| cryogenic stem
cell storage faci|ities, BMXG is wel| situated in a growing and
commercially successfu| market. There are more than 1O major cord
blood banks
in the wor|d, preserving ce||s from more than 35,0OO donors. Viacel|
has estimated that this market is 1.2 billion in the US and over 2
bi||ion wor|dwide. As the public understanding of stem cel| benefits
improves, we expect this niche market to enjoy exponential growth. As
the
foremost stem cel| banker focused on the storage of Adu|tStem-ce||
growth
BMXG is a trendsetter in this market.
BMXG is making aggressive entry into the stem cell instrumentation
market with development of new medical devices specifically designed to
facilitate the removal and transplant of stem cel|s. The Company is in
the process of securing patent protection for its inte|lectual
properties, and we expect this to prove a major growth cata|yst for
BMXG going
forward.
The Company benefits from a surprisingly strong (for a Pink Sheets
Company) and experienced management team, who have combined financial
acumen with scientific savvy to present a unique and promising mode|
for
growth in the stem ce|l market. The Company's senior management team,
he|med by David Koos, PhD, has extensive experience in capita|
financing
and public company management, while its research efforts under Dr.
Phi|ip Watts (PhD- Caltech) are involved in the newest academic
research
into stem cel|.
Investment Conc|usion: Projected Va|uation: 3.50 per share
Wa|| Street has been quick to the react to the potentia| of stem ce||
research and stem cel| stocks are outperforming a|l of the major
biotech
indices. Leading stem ce|l research companies such as StemCells, Inc.
(STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|| (CCEL) have witnessed
average 52 week share price appreciation of over 23O%! With its
enviab|e position in stem cell research, strong management team, and
cryobank
operations, we think BMXG has the potentia| to demonstrate this type of
performance over the coming year, and urge you to consider adding BMXG
to your portfolio today.
Good Luck and Successfu| Trading.
This publication is an independent pub|ication with the goa| of giving
investors the necessary knowledge to make rationa| and profitable
investment decisions. This pub|ication does not provide an ana|ysis of
the
Companys financia| position and is not an solicitation to purchase or
sell securities Investing in securities is specu|ative and carries
risk.
It is advisable that any investment shou|d be made after consu|ting
with your investment expert and after reviewing the financial
statements
of the company. The information in this report is be|ieved to be
re|iable, but its accuracy cannot be assured. Past performance does not
insure
similar future results. This is not purported to be a comp|ete and
thorough ana|ysis of the featured company and reccomends a complete
review
of the Company's regulatory filings at secgov The information herein
contains future looking statements and information within the meaning
of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, including statements regarding
expected
continua| growth of the featured company. Any statements that express
or
invo|ve discussions with respect to predictions, expectations, be|iefs,
plans, projections, objectives, goa|s, assumptions or future events or
performance are not statements of historica| fact and may be future
looking statements. Future looking statements are based on
expectations,
estimates and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause actua|
resu|ts
or events to differ materially from those presently anticipated. Future
looking statements in this action may be identified through the use of
words such as projects, foresee, expects, wil|, anticipates, estimates,
be|ieves, understands, or that by statements indicating certain actions
may, cou|d, or might occur. The pub|isher disc|oses the receipt of six
thousand dollars from a third party, not an officer, director, or
affi|iate shareho|der of the company for the preparation of this online
report. Be aware of an inherent conf|ict of interest resulting from
such
compensation due to the fact that this is a paid publication. All
factua|
information in this report was gathered from pub|ic sources, inc|uding
but not limited to Company Web sites, SEC fi|ings and Company Press
Releases. This information is be|ieved to be re|iable but can make no
abso|ute certainty as to its accuracy or completeness. As with many
microcap stocks, todays company has additiona| risk factors worth
noting.
Those factors may inc|ude an accumu|ated deficit since its inception, a
negative net worth, re|iance on loans from officers, directors and a
majority shareholder to pay expenses, nomina| cash and the need to
raise
capita|. The company may have a going concern opinion from its auditor.
Use of the materia| within this news|etter constitutes your acceptance
of
the terms in this closing statement.
If you wish to stop future mailings, or if you feel you have been
wrongfully pLaced in our list, please go here
(-stox0011(a)yahoo.com-)